Chimerix, Inc. (NASDAQ:CMRX - Get Free Report) was the target of a large growth in short interest in the month of December. As of December 15th, there was short interest totalling 3,440,000 shares, a growth of 431.1% from the November 30th total of 647,700 shares. Based on an average trading volume of 3,750,000 shares, the short-interest ratio is currently 0.9 days. Currently, 4.3% of the shares of the stock are sold short.
Institutional Trading of Chimerix
A number of hedge funds have recently modified their holdings of the business. Marshall Wace LLP purchased a new position in Chimerix during the second quarter valued at $137,000. Valeo Financial Advisors LLC increased its holdings in shares of Chimerix by 566.9% during the third quarter. Valeo Financial Advisors LLC now owns 81,766 shares of the biopharmaceutical company's stock valued at $76,000 after acquiring an additional 69,505 shares in the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. raised its position in shares of Chimerix by 66.8% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 344,712 shares of the biopharmaceutical company's stock worth $321,000 after purchasing an additional 138,098 shares during the last quarter. Institutional investors own 45.42% of the company's stock.
Analyst Ratings Changes
A number of equities research analysts recently weighed in on CMRX shares. Wedbush reaffirmed an "outperform" rating and issued a $6.00 target price on shares of Chimerix in a research note on Tuesday, December 10th. HC Wainwright restated a "buy" rating and set a $11.00 price objective on shares of Chimerix in a research report on Wednesday, December 11th.
Get Our Latest Stock Report on Chimerix
Chimerix Trading Down 3.6 %
NASDAQ CMRX traded down $0.12 during trading on Thursday, hitting $3.22. The company had a trading volume of 777,337 shares, compared to its average volume of 1,266,239. The company's fifty day moving average is $1.45 and its 200-day moving average is $1.09. The company has a market cap of $289.59 million, a price-to-earnings ratio of -3.43 and a beta of 1.02. Chimerix has a one year low of $0.75 and a one year high of $3.39.
Chimerix Company Profile
(
Get Free Report)
Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Chimerix, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Chimerix wasn't on the list.
While Chimerix currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
